Standard BioTools is a life science tools company that develops instrumentation, consumables, and services for biomedical research across proteomics and genomics applications. The company operates three core platforms—CyTOF for mass cytometry-based immune profiling, Hyperion for spatial protein imaging in tissues, and Biomark X9 for high-throughput genomic analysis—serving academic research institutions, cancer centers, translational research facilities, and biopharmaceutical companies. Standard BioTools generates revenue by selling instruments and research-use-only consumables through direct sales teams and regional distributors, targeting laboratory directors and principal investigators with sales cycles typically lasting over a year, while also pursuing original equipment manufacturer partnerships leveraging its proprietary microfluidics technology.
| USD millions | FY2025 |
|---|---|
| Revenue | 85 |
| Net Income | -75 |